• R Michael Gendreau, Lance M McCracken, David A Williams, Juan V Luciano, Yifei Dai, Nicolette Vega, Zunera Ghalib, Kristen Guthrie, Allison C Kraus, Michael J Rosenbluth, Ben Vaughn, Jennifer M Zomnir, Dana Reddy, Andrea L Chadwick, Daniel J Clauw, and Lesley M Arnold.
• Gendreau Consulting, Poway, CA, USA.
• Lancet. 2024 Jul 27; 404 (10450): 364374364-374.

BackgroundInternational guidelines have recommended cognitive behavioural therapy, including acceptance and commitment therapy (ACT), as it offers validated benefits for managing fibromyalgia; however, it is inaccessible to most patients. We aimed to evaluate the effect of a 12-week, self-guided, smartphone-delivered digital ACT programme on fibromyalgia management.MethodsIn the PROSPER-FM randomised clinical trial conducted at 25 US community sites, adult participants aged 22-75 years with fibromyalgia were recruited and randomly assigned (1:1) to the digital ACT group or an active control group that offered daily symptom tracking and monitoring and access to health-related and fibromyalgia-related educational materials. Randomisation was done with a web-based system in permuted blocks of four at the site level. We used a blind-to-hypothesis approach in which participants were informed they would be randomly assigned to one of two potentially effective therapies under evaluation. Research staff were not masked to group allocation, with the exception of a masked statistics group while preparing statistical programming for the interim analysis. The primary endpoint was patient global impression of change (PGIC) response rate at week 12. Analyses were by intention to treat. The trial was registered with ClinicalTrials.gov, NCT05243511 (now fully closed).FindingsBetween Feb 8, 2022, and Feb 2, 2023, 590 individuals were screened, of whom 275 (257 women and 18 men) were randomly assigned to the digital ACT group (n=140) and the active control group (n=135). At 12 weeks, 99 (71%) of 140 ACT participants reported improvement on PGIC versus 30 (22%) of 135 active control participants, corresponding to a difference in proportions of 48·4% (95% CI 37·9-58·9; p<0·0001). No device-related safety events were reported.InterpretationDigital ACT was safe and efficacious compared with digital symptom tracking in managing fibromyalgia in adult patients.FundingSwing Therapeutics.Copyright © Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.

23 keywords...

hide…